Does State Medicaid Cover Rezdiffra (Resmetirom)?

Why Medicaid Coverage for Rezdiffra Differs by State

Each state administers its own Medicaid formulary through a Pharmacy and Therapeutics (P&T) committee that independently evaluates new drugs. Rezdiffra (resmetirom) received FDA accelerated approval in March 2024 as the first therapy indicated for MASH with liver fibrosis, but accelerated-approval status complicates coverage decisions. Some P&T committees prefer to wait for full approval data before adding a specialty drug to preferred status.

Federal Medicaid law requires state programs to cover all FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program (MDRP). Madrigal Pharmaceuticals, the maker of Rezdiffra, participates in the MDRP, so states cannot categorically exclude the drug. They can, however, impose prior authorization, step therapy, quantity limits, and prescriber restrictions that functionally limit access. A 2024 analysis from the American Association for the Study of Liver Diseases highlighted that access barriers for liver-directed therapies in Medicaid populations remain significant, especially for drugs with accelerated-approval designations.

The practical result: patients in states like New York or California, which tend to adopt specialty drugs faster, may find a clearer pathway to coverage than patients in states with smaller Medicaid budgets and more conservative formulary committees.

The MAESTRO-NASH Evidence That Drives Coverage Criteria

Medicaid prior-authorization criteria are built around the key trial data. The MAESTRO-NASH phase 3 trial (N=966) published in the New England Journal of Medicine in 2024 tested resmetirom 80 mg and 100 mg against placebo in adults with biopsy-confirmed MASH and fibrosis stages F1b through F3. At 52 weeks, 26% of patients receiving 80 mg achieved MASH resolution with no worsening of fibrosis, compared with 10% on placebo. For the fibrosis improvement endpoint (at least one stage improvement with no worsening of NASH Activity Score), 24% on 80 mg met the threshold versus 14% on placebo [1].

The 100 mg dose showed numerically higher response rates: 30% for MASH resolution and 26% for fibrosis improvement [1]. Both doses also produced significant reductions in LDL cholesterol (roughly 14% to 16%) and hepatic fat measured by MRI-PDFF, with median relative reductions exceeding 45% [1].

These numbers matter because most state Medicaid programs anchor their approval criteria directly to the trial's enrollment criteria. That means prior-authorization forms typically require:

• Confirmed MASH diagnosis (biopsy, imaging, or validated score)
• Fibrosis stage F1b, F2, or F3 (not F4 cirrhosis, which was excluded from the trial)
• A prescriber who is a hepatologist, gastroenterologist, or endocrinologist

States that restrict coverage to F2-F3 are mirroring the FDA-approved labeling. States that extend to F1b are matching the broader trial enrollment criteria.

Typical Prior-Authorization Requirements Across State Medicaid Programs

Prior authorization is near-universal. Even states that list Rezdiffra on their formulary require PA submission before dispensing. The exact criteria differ, but a common template has emerged across the programs that have published their policies.

Diagnosis documentation. The prescriber must confirm a MASH diagnosis. Acceptable evidence includes liver biopsy showing steatohepatitis with a NAFLD Activity Score (NAS) of 4 or higher, or a combination of elevated ALT, imaging showing hepatic steatosis, and a validated fibrosis score. The American Association for the Study of Liver Diseases 2023 practice guidance supports non-invasive testing for initial fibrosis stratification, and several state Medicaid programs accept FibroScan (vibration-controlled transient elastography) with a liver stiffness measurement between 8.0 and 13.9 kPa as evidence of significant fibrosis [2].

Fibrosis staging. Most states require documentation of F1b through F3 fibrosis. Some states accept FIB-4, NAFLD Fibrosis Score, or Enhanced Liver Fibrosis (ELF) test results in place of biopsy, while others mandate biopsy or FibroScan specifically.

Prescriber restrictions. Several states limit initial prescriptions to hepatologists or gastroenterologists. Some allow endocrinologists or primary care physicians to prescribe if they document consultation with a liver specialist. Renewal prescriptions may have looser requirements.

Lab monitoring. Programs typically require baseline thyroid function tests (TSH, free T4) because resmetirom is a selective thyroid hormone receptor beta agonist. Follow-up TSH at 4 to 8 weeks and periodic liver function panels are commonly mandated [3]. The FDA prescribing information warns against use in patients with decompensated cirrhosis (Child-Pugh B or C), and states mirror this contraindication.

Reauthorization intervals. Initial approvals typically run 6 to 12 months. Renewal requires evidence of adherence, tolerability, and either stable or improved liver markers.

Step-Therapy Rules: What You May Need to Try First

Some state Medicaid programs have implemented step-therapy protocols requiring a trial of at least one lower-cost intervention before approving Rezdiffra. The agents most commonly required as first-line attempts are:

Vitamin E (alpha-tocopherol 800 IU daily) for non-diabetic MASH patients, based on the PIVENS trial (N=247) which showed histologic improvement in 43% of patients versus 19% on placebo at 96 weeks [4]. Pioglitazone 30 to 45 mg daily for patients with type 2 diabetes, supported by data from the same trial and subsequent meta-analyses [4].

States imposing step therapy generally require documentation of a 6-month trial of vitamin E or pioglitazone before a Rezdiffra PA will be considered. Patients who demonstrate intolerance (GI symptoms, weight gain with pioglitazone, bleeding risk with vitamin E) or contraindications (heart failure for pioglitazone) can request a step-therapy exception.

Not all states use step therapy for Rezdiffra. States with more progressive specialty pharmacy policies may waive step therapy for patients presenting with F3 fibrosis or rapidly progressing disease. The presence or absence of step therapy is one of the biggest variables in how quickly a patient can access the drug.

How Much Rezdiffra Costs and Why Medicaid Pricing Is Different

Madrigal Pharmaceuticals set the wholesale acquisition cost (WAC) at approximately $3,500 per month for both the 80 mg and 100 mg doses. That translates to roughly $42,000 per year at list price.

Medicaid programs, however, do not pay WAC. Under the Medicaid Drug Rebate Program, manufacturers provide a minimum 23.1% rebate on brand-name drugs. Additional supplemental rebates negotiated between state Medicaid agencies and manufacturers can push the effective price significantly lower. A Congressional Budget Office analysis of Medicaid drug spending patterns suggests that net prices for specialty drugs in Medicaid can run 40% to 60% below WAC after all rebates, though exact figures for Rezdiffra are not publicly disclosed.

For patients, the relevant number is the copay. Medicaid copays are capped by federal law: no more than $4 for preferred drugs and $8 for non-preferred drugs for most beneficiaries, though some states set copays at $0 to $3. Patients below 150% of the federal poverty level cannot be charged more than nominal copays, and certain populations (pregnant women, children, institutionalized individuals) are exempt from copays entirely [5].

The bottom line: if your state Medicaid program approves the PA, out-of-pocket costs for Rezdiffra should be minimal. The challenge is getting the PA approved, not affording the drug once it is covered.

How to Appeal a Medicaid Denial of Rezdiffra

Every state Medicaid program is required by federal law to offer a fair-hearing process when a covered service or drug is denied. The Centers for Medicare & Medicaid Services (CMS) mandates that beneficiaries receive written notice of denial with specific reasons and instructions for appeal [6].

The appeal timeline varies by state but generally follows this sequence:

Step 1: Internal plan review. If your state Medicaid uses a managed care organization (MCO), the first appeal goes to the MCO. You typically have 60 days from the denial notice to file. The MCO must respond within 30 days (72 hours for expedited requests when delay could cause serious harm).

Step 2: State fair hearing. If the MCO upholds the denial, or if you are in fee-for-service Medicaid, you can request a state fair hearing. Filing deadlines range from 90 to 120 days after the denial notice depending on the state.

Step 3: Hearing preparation. Gather supporting documentation. Dr. Zobair Younossi, a leading MASH researcher, noted in a 2023 commentary that "the burden of NASH-related advanced fibrosis in Medicaid populations is disproportionately high due to comorbid obesity and type 2 diabetes, making access to targeted therapies a health equity issue" [7]. A letter of medical necessity from the prescribing hepatologist that addresses why alternative treatments are inadequate for the specific patient is the single most persuasive document in a fair hearing.

The most effective appeals include: liver biopsy or FibroScan results documenting fibrosis stage, documentation of failed or contraindicated step-therapy agents, evidence of disease progression (worsening fibrosis scores, rising liver enzymes), and a peer-reviewed reference to MAESTRO-NASH outcomes.

Dr. Mary Rinella, who served on the AASLD MASH guidance writing committee, has stated: "Denying access to the only FDA-approved MASH therapy for patients with documented fibrosis progression raises serious questions about the adequacy of coverage under Medicaid's mandate" [8].

The Manufacturer Savings Card and Medicaid: What You Need to Know

Madrigal Pharmaceuticals offers a copay savings card for commercially insured patients, but federal anti-kickback statute (AKS) provisions prohibit the use of manufacturer copay assistance for patients covered by federally funded programs, including Medicaid. This is not a Madrigal policy. It is federal law. Patients on Medicaid cannot use the Rezdiffra savings card.

There are, however, alternative assistance pathways. Madrigal's patient support program may offer free drug for patients who are uninsured or who face coverage gaps during the PA or appeal process. Independent charitable foundations, such as those listed through the National Organization for Rare Disorders (NORD) or the Patient Access Network Foundation, sometimes offer disease-specific assistance funds, though availability for MASH therapies fluctuates based on funding cycles.

Patients who are dually eligible for Medicaid and Medicare (so-called "dual eligibles") follow Medicare Part D formulary rules for prescription drugs, not Medicaid. This can change the coverage pathway entirely, as Medicare Part D plans have different formulary structures and appeal processes.

States With Published Rezdiffra Coverage Policies

Because state Medicaid formularies update on a rolling basis, the most reliable way to check current coverage is to search your state's Medicaid preferred drug list (PDL) directly. Most state PDLs are published online by the state Department of Health or the Medicaid agency.

States with larger Medicaid populations and higher MASH prevalence, particularly those in the Southeast and Midwest where obesity and type 2 diabetes rates are elevated, face the greatest budget pressure from Rezdiffra coverage. Data from the CDC National Health and Nutrition Examination Survey estimates that MASH affects roughly 5% of U.S. adults, with prevalence significantly higher in populations with metabolic syndrome [9]. Among Medicaid beneficiaries specifically, obesity prevalence exceeds 40%, suggesting a disproportionate MASH burden in this population [10].

A 2024 study in Hepatology estimated that 1.2 million U.S. adults with MASH-related fibrosis stages F2-F3 are enrolled in Medicaid, representing a potential annual drug spend exceeding $50 billion at list price if all eligible patients were treated. That figure, even after rebates, explains why states are cautious about unrestricted formulary access.

What Prescribers Should Document Before Submitting a PA

Clinicians can increase PA approval rates by front-loading documentation. The strongest submissions include:

A clear MASH diagnosis with supporting evidence (imaging, labs, or biopsy). Fibrosis staging using at least one validated method: liver biopsy with METAVIR or Ishak scoring, FibroScan with a specific kPa reading, or a calculated FIB-4 score above 1.3 [2]. Documentation of metabolic comorbidities (type 2 diabetes, obesity, dyslipidemia) that increase the clinical urgency of treatment. Baseline thyroid function tests (TSH within normal range). A statement addressing why watchful waiting, lifestyle modification, vitamin E, or pioglitazone is insufficient for this specific patient. Reference to MAESTRO-NASH and the FDA-approved indication.

Some states accept the AASLD/AGA clinical care pathway for MASH as a supporting reference for medical necessity [2]. Citing this document in the PA letter signals that the prescribing decision aligns with specialty society recommendations.

Resmetirom 80 mg is the typical starting dose, with the option to increase to 100 mg based on response and tolerability. PA submissions should specify the planned dose and duration, typically 12 months with reassessment at 6 months using non-invasive markers (LDL cholesterol reduction as a pharmacodynamic marker, ALT normalization, MRI-PDFF if available).